Veit Buecklein – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Mon, 22 Apr 2024 12:45:23 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Veit Buecklein – VJRegenMed https://mirror.vjregenmed.com 32 32 Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy https://mirror.vjregenmed.com/video/zsz-2br52sm-investigating-real-world-outcomes-of-patients-with-rr-lbcl-after-cd19-car-t-cell-therapy/ Thu, 26 Jan 2023 12:12:01 +0000 https://mirror.vjregenmed.com/video/zsz-2br52sm-investigating-real-world-outcomes-of-patients-with-rr-lbcl-after-cd19-car-t-cell-therapy/ Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>